Keyword: Aimmune Therapeutics
Aimmune has faced some controversy with its peanut allergy med Palforzia, but the FDA decided Friday to give the drug a shot at the market.
We've assembled a list of the top 10 most-anticipated new drug launches of 2020 based on estimated global sales in 2024. Of those 10, eight could break the blockbuster barrier in four short years—putting a new batch of heavy hitters in pharma's ranks.
Peanut-allergy drugmakers Aimmune Therapeutics and DBV Technologies said ICER was premature in calling their medicines unaffordable.
AR101 could be the first drug that reduces children’s allergy reactions to accidental exposure to peanut.